Meditsinskiy sovet = Medical Council,
Год журнала:
2024,
Номер
13, С. 115 - 122
Опубликована: Сен. 2, 2024
Introduction
.
Drugs
from
the
group
of
glucagon-like
peptide-1
receptor
agonists
were
originally
intended
to
be
used
treat
patients
with
type
2
diabetes
mellitus.
However,
their
use,
a
noticeable
weight
loss
effect
was
noted,
which
expanded
list
indications
and
currently
these
drugs
are
prescribed
obese
individuals,
regardless
presence
On
Russian
market,
semavic
(semaglutide)
has
established
itself
as
an
effective
treatment
for
obesity.
Aim
To
assess
semaglutide
on
eating
behavior
in
process
loss.
Materials
methods
The
literature
search
carried
out
using
PubMed
Google
Scholar
databases.
selection
publications
according
principle
open
free
access,
analysis
abstracts
assessment
relevance.
Results
A
total
35
articles
selected
review:
7
Russian-language
28
foreign
sources.
Data
vast
majority
show
that
semavik
is
at
dose
0.5-2.4
mg
per
week
subcutaneously
course
up
68
weeks.
In
alternative
cases,
drug
taken
orally.
maximum
9,6-17,4%
initial
body
weight.
most
common
manifestation
complications
gastrointestinal
disorders,
but
only
small
number
did
they
become
reason
refuse
continue
therapy.
trials
drug,
reduction
calorie
intake
noted
absence
external
dietary
restrictions.
Conclusion
prescription
accompanied
by
increased
self-control
when
eating.
Self-control
extends
not
food,
also
drinking
alcohol.
Approximately
half
indicate
improved
quality
life.
Activation
metabolism
appears
associated
decrease
insulin
resistance,
increase
concentrations,
effects
cortisol,
hypothalamic-pituitary-adrenal
axis.
Frontiers in Microbiology,
Год журнала:
2025,
Номер
16
Опубликована: Май 27, 2025
Cognitive
impairment
is
a
decline
in
people's
ability
to
think,
learn,
and
remember,
which
has
some
impact
on
an
individual's
daily
activities
or
social
functioning.
Microbial
toxins
metabolites
from
dysregulated
gut
microbiota
directly
interact
with
the
intestinal
epithelium.
This
interaction
triggers
neuroinflammation
neurodegeneration
central
nervous
system,
ultimately
impairing
cognitive
function.
It
been
found
that
modulation
of
flora
can
be
effective
intervention
improve
dysfunction.
study
first
summarize
outline
global
research
status
trends
this
field
bibliometric
perspective,
providing
reference
guidance
for
future
field.
Based
Web
Science
Core
Collection
(WoSCC)
database,
Literature
published
between
1999-2025
was
searched.
Bibliometric
analysis
performed
using
VOSviewer
CiteSpace
software
analyze
data
countries,
institutions,
authors,
journals,
keywords,
citations,
generate
visual
maps.
A
total
1,702
pieces
related
literature
were
retrieved.
The
overall
trend
publication
increasing.
China
largest
number
papers,
Huazhong
University
&
Technology
Kim,
Dong-Hyun
institutions
individuals
more
publications.
most
frequently
cited
journal
SCI
REP-UK.
frequent
keywords
are
microbiota,
followed
by
Alzheimer's
disease,
impairment,
Brain,
oxidative
stress
Inflammation.
In
recent
years,
application
treatment
made
remarkable
progress.
Oxidative
inflammatory
response
have
become
main
hotspots
patients.
gut-brain
axis
plays
important
role
mechanism
action.
Short-chain
fatty
acids
focus
microbial
metabolism.
Fecal
transplantation
technology
increasingly
being
used
as
emerging
method
flora.
Modifying
modifying
diet
exercise
may
strategy
prevent
dysfunction
future.
Future
studies
gender
differences
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(22), С. 12125 - 12125
Опубликована: Ноя. 12, 2024
The
gut–brain
axis
(GBA)
plays
a
pivotal
role
in
human
health
and
wellness
by
orchestrating
complex
bidirectional
regulation
influencing
numerous
critical
processes
within
the
body.
Over
past
decade,
research
has
increasingly
focused
on
GBA
context
of
inflammatory
bowel
disease
(IBD).
Beyond
its
well-documented
effects
GBA–enteric
nervous
system
vagus
nerve
dysregulation,
gut
microbiota
misbalance—IBD
also
leads
to
impairments
metabolic
cellular
functions:
mitochondrial
dysfunction,
cationic
transport,
cytoskeleton
dysregulation.
These
systemic
are
currently
underexplored
relation
GBA;
however,
they
crucial
for
cells’
functioning.
This
review
summarizes
studies
particular
mechanisms
IBD.
Understanding
involvement
these
may
help
find
new
therapeutic
targets
develop
approaches
improve
quality
life
IBD
patients.
Brain Sciences,
Год журнала:
2024,
Номер
14(11), С. 1051 - 1051
Опубликована: Окт. 23, 2024
Emerging
research
into
the
human
microbiome,
an
intricate
ecosystem
of
microorganisms
residing
in
and
on
our
bodies,
reveals
that
it
plays
a
pivotal
role
maintaining
health,
highlighting
potential
for
microbiome-based
interventions
to
prevent,
diagnose,
treat,
manage
myriad
diseases.
The
objective
this
review
is
highlight
importance
microbiome
studies
enhancing
understanding
rare
genetic
epilepsy
related
neurological
disorders.
Studies
suggest
gut
acting
through
gut-brain
axis,
impacts
development
severity
epileptic
conditions
children.
Disruptions
microbial
composition
can
affect
neurotransmitter
systems,
inflammatory
responses,
immune
regulation,
which
are
all
critical
factors
pathogenesis
epilepsy.
This
growing
body
evidence
points
microbiome-targeted
therapies,
such
as
probiotics
or
dietary
modifications,
innovative
approaches
managing
By
harnessing
power
we
stand
develop
more
effective
personalized
treatment
strategies
children
affected
by
disease
other
Meditsinskiy sovet = Medical Council,
Год журнала:
2024,
Номер
13, С. 115 - 122
Опубликована: Сен. 2, 2024
Introduction
.
Drugs
from
the
group
of
glucagon-like
peptide-1
receptor
agonists
were
originally
intended
to
be
used
treat
patients
with
type
2
diabetes
mellitus.
However,
their
use,
a
noticeable
weight
loss
effect
was
noted,
which
expanded
list
indications
and
currently
these
drugs
are
prescribed
obese
individuals,
regardless
presence
On
Russian
market,
semavic
(semaglutide)
has
established
itself
as
an
effective
treatment
for
obesity.
Aim
To
assess
semaglutide
on
eating
behavior
in
process
loss.
Materials
methods
The
literature
search
carried
out
using
PubMed
Google
Scholar
databases.
selection
publications
according
principle
open
free
access,
analysis
abstracts
assessment
relevance.
Results
A
total
35
articles
selected
review:
7
Russian-language
28
foreign
sources.
Data
vast
majority
show
that
semavik
is
at
dose
0.5-2.4
mg
per
week
subcutaneously
course
up
68
weeks.
In
alternative
cases,
drug
taken
orally.
maximum
9,6-17,4%
initial
body
weight.
most
common
manifestation
complications
gastrointestinal
disorders,
but
only
small
number
did
they
become
reason
refuse
continue
therapy.
trials
drug,
reduction
calorie
intake
noted
absence
external
dietary
restrictions.
Conclusion
prescription
accompanied
by
increased
self-control
when
eating.
Self-control
extends
not
food,
also
drinking
alcohol.
Approximately
half
indicate
improved
quality
life.
Activation
metabolism
appears
associated
decrease
insulin
resistance,
increase
concentrations,
effects
cortisol,
hypothalamic-pituitary-adrenal
axis.
